"Hard to see what can be upgraded from that...but we’ll soon find out from the San Francisco bio teach meeting and the new Slide deck from that meeting."

Between the Sept 12 AGM and the latest December Corporate update and MD&A, the guidance on expected last dosing was changed from end of 2018 to H1 2019. This is ambiguous, but could also be arbitrary. We could still see last dosing Jan 2019 with follow ups, adjudication, top-line and full data all potentially finishing/reporting in H1 2019. But of course a later H1 2019 end of dosing pushes everything else out. Hopefully more clarity on the expected end of dosing to come Monday afternoon Jan 7th at Biotech Showcase. 

BearDownAZ